Advanced glycation end products (AGE) and diabetes: cause, effect, or both? - Wikidata - wikimedia - TriplyDB

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

http://www.wikidata.org/entity/Q37520014

about

Visceral adiposity syndrome Natural Phyto-Bioactive Compounds for the Treatment of Type 2 Diabetes: Inflammation as a Target Dietary advanced glycation end products and their role in health and disease Differential effects of glycation on protein aggregation and amyloid formation.Nutritional psychiatry research: an emerging discipline and its intersection with global urbanization, environmental challenges and the evolutionary mismatch Association between hemoglobin glycation index with insulin resistance and carotid atherosclerosis in non-diabetic individuals.Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.Effect of advanced glycosylation end products on apoptosis in human adipose tissue-derived stem cells in vitro.The AGE-RAGE Axis and Its Relationship to Markers of Cardiovascular Disease in Newly Diagnosed Diabetic Patients.Increased skin autofluorescence of children and adolescents with type 1 diabetes despite a well-controlled HbA1c: results from a cohort study Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study.Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.Protein pathways working in human follicular fluid: the future for tailored IVF?Effect of diet-derived advanced glycation end products on inflammation.NADPH Oxidases in Chronic Liver Diseases The influence of processed meat consumption on chronic obstructive pulmonary disease.Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression.Protective role of sulphoraphane against vascular complications in diabetes.Diabetes mellitus in patients with cirrhosis: clinical implications and management.Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?Phlorotannins: Towards New Pharmacological Interventions for Diabetes Mellitus Type 2.Carbonyl trapping and antiglycative activities of olive oil mill wastewater.Consumption of Unprocessed and Processed Red Meat and the Risk of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study of Men.Effects of age-related shifts in cellular function and local microenvironment upon the innate immune response to implants.Dietary Advanced Glycation End Products and Cardiometabolic Risk.Rosmarinic acid modulates the antioxidant status and protects pancreatic tissues from glucolipotoxicity mediated oxidative stress in high-fat diet: streptozotocin-induced diabetic rats.N-acetylcysteine Counteracts Adipose Tissue Macrophage Infiltration and Insulin Resistance Elicited by Advanced Glycated Albumin in Healthy Rats.The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications Matrine-Type Alkaloids Inhibit Advanced Glycation End Products Induced Reactive Oxygen Species-Mediated Apoptosis of Aortic Endothelial Cells In Vivo and In Vitro by Targeting MKK3 and p38MAPK Signaling.A Retrospective Study in Adults with Metabolic Syndrome: Diabetic Risk Factor Response to Daily Consumption of Agaricus bisporus (White Button Mushrooms).Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study.Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.Attenuation of Glucose-Induced Myoglobin Glycation and the Formation of Advanced Glycation End Products (AGEs) by (R)-α-Lipoic Acid In Vitro.Advanced Glycation-Modified Human Serum Albumin Evokes Alterations in Membrane and Eryptosis in Erythrocytes.Peripheral Levels of AGEs and Astrocyte Alterations in the Hippocampus of STZ-Diabetic Rats.Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients.Evaluation of methylglyoxal toxicity in human erythrocytes, leukocytes and platelets.Potential involvement of dietary advanced glycation end products in impairment of skeletal muscle growth and muscle contractile function in mice.Advanced glycation end products-induced insulin resistance involves repression of skeletal muscle GLUT4 expression.Neuronal damage and shortening of lifespan in C. elegans by peritoneal dialysis fluid: Protection by glyoxalase-1.

P2860

Q26738890-D2174FE9-8F95-48BE-8FF0-1A69845AA675 Q26741391-5B63D48F-3AB6-4CFB-9748-67FCEAE23F63 Q26801247-2208DE0D-2AC8-4878-84C2-116162241607 Q30374807-3C413746-BAB8-421D-A388-357592CFB7CF Q30838578-843364B0-5FD3-4FDD-B566-08C4FE88A7CB Q33584606-D360C885-1EDF-4219-B8BB-EC85BE13F761 Q35255473-E3FAA93C-5E97-4659-8165-BC89FDA0B422 Q35600704-F0A0DD78-7FE3-48A8-B95A-55A131AA1EEE Q36081850-C28A5BDF-5911-490B-8C30-EDEC7D794696 Q36128952-298F686A-3916-45ED-B840-C3948B89DB3E Q37056383-1B630421-9E08-4F3F-BC42-E0716B216D2F Q38315999-42CD4025-74F4-4831-972E-1BADD2B87D13 Q38447792-6C534982-A1C5-4DA3-94E0-4B43DD9D4FC5 Q38588208-2E6C9AEA-497C-4976-B4ED-C96D9857A384 Q38599090-AB9C1B7B-74B5-4269-8F3A-781867763044 Q38616696-CF63AD3B-6EDF-4439-9904-5E032468ED36 Q38698770-B6A50D2E-A0CE-4FA8-91DE-A60B0D48A9C6 Q38721709-8BD1DFB7-B80E-4838-999B-9C950114835C Q38773241-BB640A96-ED05-40BE-AB64-88F2AB30E50B Q39036315-C2C91778-F2C8-43C6-9C7B-F9C52DDD627E Q39064669-8A73DC23-A9C8-428E-B18A-6A4DDBAC698D Q39073641-F6060D5E-5AE7-4851-9B06-AE91E62F6181 Q39241882-5731FD6B-4B8E-4D20-8B36-A243E2355704 Q39327060-50DA43F8-7C33-42AC-8056-C6C05B377E4F Q39427655-B431219C-7278-4D77-B9D0-544B0252EE87 Q41307634-A61969F5-D72B-4AD6-BFE4-B25BA9E685EB Q42161720-0213D93D-F214-4A38-9C1E-AB510708A08E Q42226832-04F7F5A2-2C65-4EF7-9C75-70105D7952FA Q46249392-9F5BD5B2-7488-41C4-ABE4-FDCA8A865380 Q47427273-EBAA61FC-BAB4-4DFC-B852-9E97B61B3C7C Q48178877-113E5585-AFAB-4942-8AAB-326EF67B5883 Q49833824-C49873BC-1E8D-48E9-A0BB-97C3605C9F39 Q50117388-51078803-8386-411A-9A64-D9C47278593B Q50438327-3822E45F-519F-4B83-93AF-532C1063A011 Q50655623-914EE355-7FCF-4246-A192-D8589FBF4E16 Q51127315-26DCD903-AE04-4A33-97D1-CFCE249D3ED5 Q51175353-4A302395-532F-4517-971F-C0C5020B7F22 Q51187983-C48C972F-E7F6-422E-8145-BF1778FD810B Q54986288-FC636B52-EBE4-490A-871C-4CD42DADAB79 Q55075595-1FA9449A-A0E2-41BA-9FFB-0A08B95A7F8D

P2860

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

http://www.wikidata.org/entity/Q37520014

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

@en

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

@nl

type

label

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

@en

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

@nl

prefLabel

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

@en

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

@nl

P1433

Q37520014-458B7871-FA15-42CA-831A-11BF4E93D05B

P1476

Q37520014-EBE6C932-4801-4561-8AE0-B36FDF5DA257

P2093

Q37520014-022912F5-7794-4C05-84BB-08A47F106E59

Q37520014-0974F3C7-B4D8-45BC-B452-E7BC7290F43D

P2860

Q37520014-0170EA12-4EE0-4A26-94E9-E6DA8DF84E6B

Q37520014-0ADBA080-9D78-4B5E-8903-138CF3FED8F9

Q37520014-0F893F1A-BD55-48A2-870D-017A87CF825F

Q37520014-147129EF-57D2-46C0-9517-49A8C3B68524

Q37520014-20F0F7EC-6F90-48CE-B597-77E52AFC2FC9

Q37520014-26F92CE9-6EFB-4904-B77B-5CFCDDD6D6BB

Q37520014-2798EAB4-818F-4BD7-96D4-A1C9E22A3481

Q37520014-282B7CB6-4874-43E6-B7AD-36BB4D8E8EF6

Q37520014-28B728AD-BCCA-42F2-A974-190610778C35

Q37520014-2F593425-9A58-495F-8C54-CAF3D08208BE

P2888

Q37520014-7154EBB9-9091-404D-BB49-96BB118335D7

P304

Q37520014-63E970F7-EBED-41AF-A822-7EFB846EDE16

P31

Q37520014-CAA6F52D-EBC9-465E-A64D-CCE35C35F133

P356

Q37520014-07F95594-77FB-4F33-A3C5-7A5A620C6025

P433

Q37520014-7CCE2C71-E1A9-4785-ACB9-755B27633766

P478

Q37520014-81D41AC3-5B00-487A-9257-7B1BFEB24A59

P577

Q37520014-3FE9DEE4-3851-44FC-9859-1E57B028D494

P698

Q37520014-8FCB2DBD-3880-475D-8C88-A5FACA8B30F3

P932

Q37520014-E8C1956D-3BA7-479F-9B55-9C8610E32BCF

P356

S11892-013-0453-1

P1433

Current diabetes report

P1476

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

@en

P2093

Helen Vlassara

http://www.w3.org/2001/XMLSchema#string

Jaime Uribarri

http://www.w3.org/2001/XMLSchema#string

P2860

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells

Advanced glycation end products in foods and a practical guide to their reduction in the diet

Tobacco smoke is a source of toxic reactive glycation products

Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Biochemistry and molecular cell biology of diabetic complications

Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Glucose control and vascular complications in veterans with type 2 diabetes

P2888

s11892-013-0453-1

P304

453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11892-013-0453-1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24292971

http://www.w3.org/2001/XMLSchema#string

P932

3903318

http://www.w3.org/2001/XMLSchema#string